Impact of COVID-19 on cancer service delivery: a follow-up international survey of oncology clinicians.

COVID-19 Follow-Up Studies Humans Neoplasms / epidemiology Pandemics SARS-CoV-2 Surveys and Questionnaires
COVID-19 oncology service delivery telehealth

Journal

ESMO open
ISSN: 2059-7029
Titre abrégé: ESMO Open
Pays: England
ID NLM: 101690685

Informations de publication

Date de publication:
10 2021
Historique:
received: 27 05 2021
revised: 18 06 2021
accepted: 06 07 2021
pubmed: 31 8 2021
medline: 29 10 2021
entrez: 30 8 2021
Statut: ppublish

Résumé

The COVID-19 pandemic has had a vast impact on cancer service delivery around the world. Previously reported results from our international survey of oncology clinicians, conducted through March-April 2020, found that clinicians reported altering management in both the curative and palliative settings and not in proportion to the COVID-19 case burden in their region of practice. This follow-up survey, conducted from 27 Participants were medical, radiation and surgical oncologist and trainees. Surveys were distributed electronically via ESMO and other collaborating professional societies. Participants were asked to compare their practice prior to the pandemic to both the period of March-April 2020, referred to as the 'early' period, and the current survey period, referred to as the 'later' period. One hundred and seventy-two oncology clinicians completed the survey. The majority of respondents were medical oncologists (n = 136, 79%) and many were from Europe (n = 82, 48%). In the 'early' period, 88% (n = 133) of clinicians reported altering their practice compared to 63% (n = 96) in the 'later' period. Compared to prior to the pandemic, clinicians reported fewer new patient presentations in the 'early' period and a trend towards more patients presenting with advanced disease in the 'later' period. Results indicate a swing back towards pre-COVID-19 practices despite an increase in the rate of cumulative COVID-19 cases across 2020. The impact of these changes on cancer associated morbidity and mortality remains to be measured over the months and years to come.

Sections du résumé

BACKGROUND
The COVID-19 pandemic has had a vast impact on cancer service delivery around the world. Previously reported results from our international survey of oncology clinicians, conducted through March-April 2020, found that clinicians reported altering management in both the curative and palliative settings and not in proportion to the COVID-19 case burden in their region of practice. This follow-up survey, conducted from 27
PARTICIPANTS AND METHODS
Participants were medical, radiation and surgical oncologist and trainees. Surveys were distributed electronically via ESMO and other collaborating professional societies. Participants were asked to compare their practice prior to the pandemic to both the period of March-April 2020, referred to as the 'early' period, and the current survey period, referred to as the 'later' period.
RESULTS
One hundred and seventy-two oncology clinicians completed the survey. The majority of respondents were medical oncologists (n = 136, 79%) and many were from Europe (n = 82, 48%). In the 'early' period, 88% (n = 133) of clinicians reported altering their practice compared to 63% (n = 96) in the 'later' period. Compared to prior to the pandemic, clinicians reported fewer new patient presentations in the 'early' period and a trend towards more patients presenting with advanced disease in the 'later' period.
CONCLUSIONS
Results indicate a swing back towards pre-COVID-19 practices despite an increase in the rate of cumulative COVID-19 cases across 2020. The impact of these changes on cancer associated morbidity and mortality remains to be measured over the months and years to come.

Identifiants

DOI: 10.1016/j.esmoop.2021.100224 PMID: 34461484 PMC: PMC8405899
pubmed: 34461484
pii: S2059-7029(21)00185-X
doi: 10.1016/j.esmoop.2021.100224
pmc: PMC8405899
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

100224

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Disclosure GC is receiving a Research Training Program Scholarship from the University of Melbourne as part of her higher degree. SB, FL and SP hold leadership positions on the ESMO Executive Board. All other authors have declared no conflicts of interest.

Références

ESMO Open. 2021 Apr;6(2):100058
pubmed: 33601295
Asia Pac J Clin Oncol. 2021 Aug;17(4):359-367
pubmed: 33567163
J Oncol Pract. 2018 Jul;14(7):e429-e437
pubmed: 29996068
JAMA Netw Open. 2020 Aug 3;3(8):e2017267
pubmed: 32749465
ESMO Open. 2020 Dec;5(6):e001090
pubmed: 33262203
Intern Med J. 2021 Jan;51(1):125-133
pubmed: 33572014
Lancet Oncol. 2020 Jun;21(6):750-751
pubmed: 32359403
Nat Rev Drug Discov. 2020 Jun;19(6):376-377
pubmed: 32424343
Ann Oncol. 2020 Oct;31(10):1320-1335
pubmed: 32745693
JCO Glob Oncol. 2021 Feb;7:162-172
pubmed: 33529077
Lancet Oncol. 2020 Aug;21(8):1023-1034
pubmed: 32702310

Auteurs

G Chazan (G)

Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia.

F Franchini (F)

Centre for Cancer Research and Centre for Health Policy, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, Australia; Melbourne School of Public and Global Health, Faculty of Medicine, Dentistry and Health Sciences, Parkville, Australia; Department of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Australia.

M Alexander (M)

Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia; Department of Pharmacy, Peter MacCallum Cancer Centre, Melbourne, Australia.

S Banerjee (S)

Gynaecology Unit, The Royal Marsden NHS Foundation Trust, London, UK; Division of Clinical Studies, The Institute of Cancer Research, London, UK.

L Mileshkin (L)

Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.

P Blinman (P)

Faculty of Medicine, University of Sydney, Sydney, Australia; Medical Oncology, Concord Repatriation General Hospital, Concord, Australia.

R Zielinski (R)

Medical Oncology, Western Sydney University, Sydney, Australia; Medical Oncology, Orange Hospital, Western New South Wales Local Health District, Orange, Australia.

D Karikios (D)

Medical Oncology, Nepean Hospital, Sydney, Australia; Nepean Clinical School, University of Sydney, Sydney, Australia.

N Pavlakis (N)

Medical Oncology, Royal North Shore Hospital, Sydney, Australia.

S Peters (S)

Medical Oncology, Lausanne University Hospital CHUV, Lausanne, Switzerland.

F Lordick (F)

University Cancer Centre Leipzig, University Medicine Leipzig, Leipzig, Germany.

D Ball (D)

Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia; Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.

G Wright (G)

St Vincent's Hospital, Victorian Comprehensive Cancer Centre, Fitzroy, Australia; Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia; Department of Surgery, University of Melbourne, Parkville, Australia.

M IJzerman (M)

Centre for Cancer Research and Centre for Health Policy, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, Australia; Department of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Australia; University of Twente, Health Technology & Services Research, Enschede, The Netherlands.

B J Solomon (BJ)

Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia; Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia. Electronic address: Ben.solomon@petermac.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › COVID-19 › Impact of COVID-19 on cancer service delivery:...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études de suivi › Impact of COVID-19 on cancer service delivery:...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Impact of COVID-19 on cancer service delivery:...
questionsmedicales.fr › Tumeurs › Impact of COVID-19 on cancer service delivery:...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Épidémies de maladies › Épidémies › Pandémies › Impact of COVID-19 on cancer service delivery:...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Nidovirales › Coronaviridae › Coronavirus › Betacoronavirus › Virus du SRAS › SARS-CoV-2 › Impact of COVID-19 on cancer service delivery:...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Enquêtes et questionnaires › Impact of COVID-19 on cancer service delivery:...